Trial Profile
A Randomized Control Trial Comparing Peginterferon-α-2a Versus Observation After Stopping Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia With Deep Molecular Response for at Least Two Years
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms MSIT
- 01 Nov 2018 Planned End Date changed from 1 Mar 2019 to 1 Oct 2021.
- 01 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.